194156-55-3

Basic information

• Product Name: 3-BOC-AMINOBUTYRONITRILE
• Synonyms: 3-BOC-AMINOBUTYRONITRILE;Carbamic acid, (2-cyano-1-methylethyl)-, 1,1-dimethylethyl ester (9CI);(2-Cyano-1-methyl-ethyl)-carbamic acid tert-butyl ester
• CAS NO: 194156-55-3
• Molecular Formula: C9H16N2O2
• Molecular Weight: 184.24
• Product Categories: N-BOC
• Mol File: 194156-55-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BOC-AMINOBUTYRONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BOC-AMINOBUTYRONITRILE(194156-55-3)
• EPA Substance Registry System: 3-BOC-AMINOBUTYRONITRILE(194156-55-3)

Safety Data

• Hazardous Substances Data: 194156-55-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-BOC-AMINOBUTYRONITRILE is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure and reactivity make it a valuable component in the development of new medications.
Used in Agrochemical Production:
In the agrochemical sector, 3-BOC-AMINOBUTYRONITRILE serves as an intermediate in the production of different agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Organic Compound Synthesis:
3-BOC-AMINOBUTYRONITRILE is utilized as an intermediate in the synthesis of a range of organic compounds, highlighting its versatility in organic chemistry.
Used in Chemical Research and Drug Development:
3-BOC-AMINOBUTYRONITRILE is used as a building block for the production of new compounds with biological activities in the field of chemical research. Its potential in drug development is being explored due to its distinctive chemical properties and reactivity.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 773837-37-9 sodium cyanide 
• 352705-03-4 (2R)-2-[(tert-butoxycarbonyl)amino]propyl 4-methylbenzene-1-sulfonate 
• 126301-16-4 (2R)-2-[(tert-butoxycarbonyl)amino]propyl methanesulfonate 
• 79069-13-9 (R)-2-tertbutoxycarbonylamino-1-propanol 
• 143-33-9 sodium cyanide 
• 16750-40-6 (+-)-3-amino-butyronitrile 
• 84765-24-2 (S)-O-(p-tolylsulfonyl)-N-(tert-butyloxycarbonyl)-1-hydroxy-2-aminopropane 
• 109208-68-6 Boc-Ala-O-COO-isoBu 
• 15761-38-3 L-N-Boc-Ala 
• 126301-16-4 (2S)-2-[(tert-butoxycarbonyl)amino]propyl methanesulfonate 
• 79069-13-9 (S)-2-t-butoxycarbonylaminopropan-1-ol 
• 13435-20-6 tetraethylammoniumcyanide 
• 161529-20-0 tert-butyl N-[(1S)-2-iodo-1-methylethyl]carbamate 

Downstream Products

• 6078-06-4 (S)-methyl 3-aminobutanoate 
• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 
• 172695-22-6 (2-cyano-1(S)-methylethyl)carbamic acid, 1,1-dimethylethyl ester 
• 170367-68-7 (2-cyano-1(R)-methylethyl)carbamic acid, 1,1-dimethylethyl ester 
• 6078-06-4 (R)-methyl 3-aminobutanoate hydrochloride 
• 159991-23-8 (R)-3-((tert-butoxycarbonyl)amino)butanoic acid 
• 170367-69-8 (3-amino-1(R)-methylpropyl)carbamic acid, 1,1-dimethylethyl ester 
• 118173-26-5 (S)-3-tert-butoxycarbonylamino-butanal 
• 176982-57-3 (3-amino-1(S)-methylpropyl)carbamic acid, 1,1-dimethylethyl ester 
• 679808-74-3 (3S)-3-aminobutanenitrile 

Relevant articles and documents

HETEROCYCLIC GLP-1 AGONISTS

This disclosure relates to GLP-1 agonists of Formula (I) : including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Process Optimisation Studies and Aminonitrile Substrate Evaluation of Rhodococcus erythropolis SET1, A Nitrile Hydrolyzing Bacterium

A comprehensive series of optimization studies including pH, solvent and temperature were completed on the nitrile hydrolyzing Rhodococcus erythropolis bacterium SET1 with the substrate 3-hydroxybutyronitrile. These identified temperature of 25 °C and pH of 7 as the best conditions to retain enantioselectivity and activity. The effect of the addition of organic solvents to the biotransformation mixture was also determined. The results of the study suggested that SET1 is suitable for use in selected organo-aqueous media at specific ratios only. The functional group tolerance of the isolate with unprotected and protected β-aminonitriles, structural analogues of β-hydroxynitriles was also investigated with disappointingly poor isolated yields and selectivity obtained. The isolate was further evaluated with the α- aminonitrile phenylglycinonitrile generating acid in excellent yield and ee (>99 % (S) – isomer and 50 % yield). A series of pH studies with this substrate indicated pH 7 to be the optimum pH to avoid product and substrate degradation.

Synthesis and evaluation of chiral β-amino acid-based low-molecular-weight organogelators possessing a methyl/trifluoromethyl side chain

The synthesis and gelation properties of chiral β-amino acid-based low-molecular-weight organogelators, possessing methyl/trifluoromethyl side chains, are reported. The structure of the side chain and chirality were found to be important parameters affecting the gelation ability. The pure enantiomer of the trifluoromethylated β-amino acid displayed good gelation properties due to the formation of fibrillar networks, driven by enhanced amide hydrogen bonding. An investigation of the effects of the alkyl chain length showed that longer alkyl chain improved the gelation ability, yet the same supramolecular structure was observed in all, as well as an odd-even effect in both the melting points and Tg values.

Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide

The design, synthesis, and structure activity relationships of the novel class of pyrazolylethylbenzamide orexin receptor 1-selective antagonists are described. Further derivatization of the prototype dual orexin receptor 1/2 antagonist lead (1) by instal

Synthetic and theoretical investigation on the one-pot halogenation of β-amino alcohols and nucleophilic ring opening of aziridinium ions

Aziridinium ions are useful reactive intermediates for the synthesis of enantiomerically enriched building blocks. However, N,N-dialkyl aziridinium ions are relatively underutilized in the synthesis of optically active molecules as compared to other three

BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE

A branched chain alkyl heteroaromatic ring derivative represented by formula (Ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of the orexin (OX) receptor antagonist activity.

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

A multifaceted secondary structure mimic based on piperidine-piperidinones

Minimalist secondary structure mimics are typically made to resemble one interface in a protein-protein interaction (PPI), and thus perturb it. We recently proposed suitable chemotypes can be matched with interface regions directly, without regard for secondary structures. Here we describe a modular synthesis of a new chemotype 1, simulation of its solution-state conformational ensemble, and correlation of that with ideal secondary structures and real interface regions in PPIs. Scaffold 1 presents amino acid side-chains that are quite separated from each other, in orientations that closely resemble ideal sheet or helical structures, similar non-ideal structures at PPI interfaces, and regions of other PPI interfaces where the mimic conformation does not resemble any secondary structure. 68 different PPIs where conformations of 1 matched well were identified. A new method is also presented to determine the relevance of a minimalist mimic crystal structure to its solution conformations. Thus dld-1-faf crystallized in a conformation that is estimated to be 0.91 kcal-mol-1 above the minimum energy solution state. Do we know, when designing a new peptidomimetic scaffold like the one shown, how it can resemble secondary structures? Design and modular synthesis of this elongated mimic is reported, and the structure is related to ideal and real structures at PPI interfaces.

Practical convergent laboratory-scale synthesis of a CCR5 receptor antagonist

An efficient laboratory-scale synthesis has been developed for the selective CCR5 antagonist 1. The convergent route has a longest linear sequence of nine steps (15 steps overall), and has overall yields of 18-25%. The route has enabled the preparation of 550 g of 1.

Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of α-glycoprotein were evaluated in rat and dog pharmacokinetics.